site stats

Chapter 18a hkex

WebNov 26, 2024 · The exchange’s momentum could be attributed to listing reforms introduced in 2024 that allowed pre-revenue biotech companies to raise funding through a path called Chapter 18A, which, among other things, requires biotech applicants to have at least two years of operations in the same line of business and an initial market capitalization of ... WebIn addition, Chapter 18A imposes disclosure requirements specific to Biotech Companies. In April 2024, the Stock Exchange also released Guidance Letter HKEX-GL107-205, which provides further guidance on disclosure in listing documents for Biotech Companies.

An Easier Road to a Hong Kong Listing for Biotech Companies

WebJun 29, 2024 · Since the introduction of Chapter 18A in 2024, which allows listing for pre-revenue biotech companies, the HKEx has cultivated the development of a viable eco system for fundraising of healthcare and life sciences companies, which has generated a steady flow of listings of biotech companies. Weband the retail market toward Chapter 18A over the past two years. To further develop this chapter and the biotech ecosystem in Hong Kong, on 30 April 2024 the HKEX published new and updated guidance letters for pre-revenue biotech companies, providing prospective issuers and the market with more clarity on the requirements for listing and required can you buy a fennec fox as a pets https://connersmachinery.com

2024 HKEX Biotech Listings Drop from Last Year’s Record High

WebJul 10, 2024 · HKEx further clarifies that (i) an existing shareholder holding less than 10% of the shares in the biotech company may subscribe for shares in the IPO as either a cornerstone investor or as a... WebJul 3, 2024 · HKEX closed 2024 with a total of 92 biotech and healthcare listings on its main board, raising a total of HKD 255 billion (USD 32.6 billion) since the launch of the internal reforms. The figure includes 48 pre-revenue biotech companies that have listed under Chapter 18A, raising a total of HKD 112.6 billion (USD 14.4 billion). WebApr 13, 2024 · Being approved to drop the "B" marker from its stock short name indicates that a biotech company listed at the HKEX under Chapter 18A of the listing rules has met higher standards for revenue, market cap, etc. ... Shortly after the company was listed on the main board of the HKEX on December 30, 2024, it was included in the Shanghai-Hong … briggs and stratton intek horizontal engine

2024 HKEX Biotech Listings Drop from Last Year’s Record High

Category:Chapter 18A - Hong Kong Stock Exchange

Tags:Chapter 18a hkex

Chapter 18a hkex

Listing of Pre-Revenue Biotech Companies in Hong Kong

WebApr 28, 2024 · In the Consultation Conclusions, the HKEX permits existing shareholders to participate in the IPO of a Chapter 18A Applicant provided that the issuer complies with both the existing Listing Rule 8.08(1) (mainly with respect to the minimum 25% public float requirement) and the new Listing Rule 18A.07 in relation to shares held by the public. [7] WebObservations from listed Chapter 18A biotechnology companies prospectuses Core Products and Competent Authorities. A biotechnology company applying for listing under Chapter 18A must have developed at least one Core Product beyond the concept stage. The Core Products of Hua Medicine, BeiGene and Acsletis all fall within the category of …

Chapter 18a hkex

Did you know?

WebDec 9, 2024 · The four companies listed under the HKEX’s Chapter 18A – a tool introduced in 2024 that allows pre-revenue biotech companies to raise funding – so far in 2024 are Lepu Biopharma, Jiangsu Recbio Technologies, Rainmed Medical and Biocytogen Pharmaceuticals. The key requirements contained in Chapter 18A, and the related … WebWorking alongside innovators, research institutes, investors and the wider global healthcare industry, HKEX is committed to supporting the sector, by providing platforms that help steer the industry towards investments and …

WebBiotech companies seeking to list on HKEx under Chapter 18A of the Listing Rules must have at least one “core product” that (i) has completed Phase 1 clinical trials (clinical trials on human subjects categorized as Phase 1 clinical trials by the a regulatory authority recognized by HKEx), and (ii) for which the relevant competent authority … WebApr 11, 2024 · A Biotech Company listed under Chapter 18A of the Listing Rules has its name that ends with the marker "B". A Special Purpose Acquisition Company listed under Chapter 18B of the Listing Rules has its name that ends with marker “Z”. A Secondary listing company in Hong Kong has its name that ends with the marker “S”. New Listing …

WebHKEX has applied the principles of the Corporate Governance Code to its corporate governance structure and practices. Corporate Social Responsibility Our Approach Our Approach Strategy Governance Stakeholder Engagement Our Markets Our Markets Corporate Governance Environmental, Social and Governance (ESG) Sustainable Finance

WebJan 14, 2024 · The introduction of Chapter 18A marks an important first step towards broadening Hong Kong’s listing regime to pre-revenue companies and has received encouraging results so far.

WebMar 28, 2024 · In February 2024, the HKEx published a draft of the new Chapter 18A of the Main Board Listing Rules which sets out the listing requirements and guidance for a pre-revenue biotech company which is unable to meet the current Main Board financial eligibility tests on profit, revenue and market capitalization (see Note below). ... can you buy a firearm with a misdemeanorWebMay 3, 2024 · It should also be noted that not all types of biotech products are automatically accommodated by the rules under the new Chapter 18A. Biotech products which do not fall into the categories set out in Guidance Letter HKEX-GL92-18 will be considered by the Exchange on a case by case basis. The Exchange has indicated that in these … can you buy a firearm onlineWebAnswer: To establish whether an applicant is "innovative" for the purpose of Chapter 8A, the Exchange will take into consideration the characteristics set out in paragraph 4.2 of GL93-18 (or as the case may be, paragraph 3.2 of GL94-18). An innovative company would normally be expected to possess more than one of the characteristics set out in ... briggs and stratton intek piston clearance